King's College London

Research portal

Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis

Research output: Contribution to journalArticle

Standard

Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis. / Merritt, Kate; McGuire, Philip; Egerton, Alice.

In: Frontiers in psychiatry / Frontiers Research Foundation, Vol. 4, No. N/A, 151, 16.11.2013, p. N/A.

Research output: Contribution to journalArticle

Harvard

Merritt, K, McGuire, P & Egerton, A 2013, 'Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis', Frontiers in psychiatry / Frontiers Research Foundation, vol. 4, no. N/A, 151, pp. N/A. https://doi.org/10.3389/fpsyt.2013.00151

APA

Merritt, K., McGuire, P., & Egerton, A. (2013). Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis. Frontiers in psychiatry / Frontiers Research Foundation, 4(N/A), N/A. [151]. https://doi.org/10.3389/fpsyt.2013.00151

Vancouver

Merritt K, McGuire P, Egerton A. Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis. Frontiers in psychiatry / Frontiers Research Foundation. 2013 Nov 16;4(N/A):N/A. 151. https://doi.org/10.3389/fpsyt.2013.00151

Author

Merritt, Kate ; McGuire, Philip ; Egerton, Alice. / Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis. In: Frontiers in psychiatry / Frontiers Research Foundation. 2013 ; Vol. 4, No. N/A. pp. N/A.

Bibtex Download

@article{8e3a5d03e4744165b59708c08b95616b,
title = "Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis",
abstract = "The glutamate hypothesis of schizophrenia, proposed over two decades ago, originated following the observation that administration of drugs that block NMDA glutamate receptors, such as ketamine, could induce schizophrenia-like symptoms. Since then, this hypothesis has been extended to describe how glutamate abnormalities may disturb brain function and underpin psychotic symptoms and cognitive impairments. The glutamatergic system is now a major focus for the development of new compounds in schizophrenia. Relationships between regional brain glutamate function and symptom severity can be investigated using proton magnetic resonance spectroscopy (1H-MRS) to estimate levels of glutamatergic metabolites in vivo. Here we briefly review the 1H-MRS studies that have explored relationships between glutamatergic metabolites, symptoms, and cognitive function in clinical samples. While some of these studies suggest that more severe symptoms may be associated with elevated glutamatergic function in the anterior cingulate, studies in larger patient samples selected on the basis of symptom severity are required.",
author = "Kate Merritt and Philip McGuire and Alice Egerton",
year = "2013",
month = "11",
day = "16",
doi = "10.3389/fpsyt.2013.00151",
language = "English",
volume = "4",
pages = "N/A",
journal = "Frontiers in psychiatry / Frontiers Research Foundation",
issn = "1664-0640",
publisher = "Frontiers",
number = "N/A",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis

AU - Merritt, Kate

AU - McGuire, Philip

AU - Egerton, Alice

PY - 2013/11/16

Y1 - 2013/11/16

N2 - The glutamate hypothesis of schizophrenia, proposed over two decades ago, originated following the observation that administration of drugs that block NMDA glutamate receptors, such as ketamine, could induce schizophrenia-like symptoms. Since then, this hypothesis has been extended to describe how glutamate abnormalities may disturb brain function and underpin psychotic symptoms and cognitive impairments. The glutamatergic system is now a major focus for the development of new compounds in schizophrenia. Relationships between regional brain glutamate function and symptom severity can be investigated using proton magnetic resonance spectroscopy (1H-MRS) to estimate levels of glutamatergic metabolites in vivo. Here we briefly review the 1H-MRS studies that have explored relationships between glutamatergic metabolites, symptoms, and cognitive function in clinical samples. While some of these studies suggest that more severe symptoms may be associated with elevated glutamatergic function in the anterior cingulate, studies in larger patient samples selected on the basis of symptom severity are required.

AB - The glutamate hypothesis of schizophrenia, proposed over two decades ago, originated following the observation that administration of drugs that block NMDA glutamate receptors, such as ketamine, could induce schizophrenia-like symptoms. Since then, this hypothesis has been extended to describe how glutamate abnormalities may disturb brain function and underpin psychotic symptoms and cognitive impairments. The glutamatergic system is now a major focus for the development of new compounds in schizophrenia. Relationships between regional brain glutamate function and symptom severity can be investigated using proton magnetic resonance spectroscopy (1H-MRS) to estimate levels of glutamatergic metabolites in vivo. Here we briefly review the 1H-MRS studies that have explored relationships between glutamatergic metabolites, symptoms, and cognitive function in clinical samples. While some of these studies suggest that more severe symptoms may be associated with elevated glutamatergic function in the anterior cingulate, studies in larger patient samples selected on the basis of symptom severity are required.

U2 - 10.3389/fpsyt.2013.00151

DO - 10.3389/fpsyt.2013.00151

M3 - Article

VL - 4

SP - N/A

JO - Frontiers in psychiatry / Frontiers Research Foundation

JF - Frontiers in psychiatry / Frontiers Research Foundation

SN - 1664-0640

IS - N/A

M1 - 151

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454